Vulvar Adenocarcinoma

1. Disease Information

1.1 What is the disease?

Vulvar adenocarcinoma refers to malignant epithelial tumors of the vulva with glandular differentiation. In vulvar cancer, squamous cell carcinoma (SCC) is predominant (>90%), and adenocarcinomas are uncommon. Rarer vulvar histologies explicitly recognized in contemporary guidelines include extramammary Paget’s disease and Bartholin gland adenocarcinoma, among others. (aburustum2024vulvarcancerversion pages 1-2, ha2024imaginginvulval pages 1-2)

1.2 Key identifiers (available from retrieved sources)

• ICD-10 (vulvar cancer overall): C51 (vulvar cancer) used in an administrative-database study. (muigai2018potentialdelayin pages 1-2)
• ICD-10 related codes used as “pre-diagnosis” mimics/overlaps: Bartholin gland diseases N75; inflammation of vagina/vulva N76; other vulvar noninflammatory disorders N90.5–N90.9. (muigai2018potentialdelayin pages 1-2)
• FIGO staging: FIGO 2021 applies to vulvar cancers of all morphologic types except melanoma and incorporates imaging in staging; depth of invasion measurement is specified. (ha2024imaginginvulval pages 1-2, ha2024imaginginvulval media 862afa93)
• WHO classification: Vulvar adenocarcinomas should be diagnosed/subtyped using the WHO 2020 classification (as referenced in reporting standards). (faruqi2018standardsanddatasets pages 12-16)

Unavailable with current tool evidence: OMIM, Orphanet, MeSH IDs, MONDO ID.

1.3 Synonyms / alternative names (subtype-level)

• Intestinal-type vulvar adenocarcinoma (VAIt): WHO 2020 describes “primary villo-glandular mucinous adenocarcinoma exhibiting intestinal differentiation” and discourages “cloacogenic carcinoma/adenocarcinoma” terminology. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 1-2)
• Adenocarcinoma of mammary gland type (AMGT) / mammary-like gland adenocarcinoma of vulva. (morais2022diagnosisandmanagement pages 1-2)
• Extramammary Paget’s disease (EMPD) of vulva; can be invasive or represent manifestation of underlying vulvar adenocarcinoma per Wilkinson/Brown subclassification. (iacobone2023tipsandtricks pages 2-4)

1.4 Evidence source type

• Predominantly aggregated resources (NCCN guideline; imaging guideline review; staging/reporting standards) plus cohort/registry analyses (SEER metastatic vulvar cancer; EMPD referral-center cohort; Bartholin carcinoma institutional cohort) and case reports (mammary-like adenocarcinoma; metastatic HER2+ EMPD WGS). (aburustum2024vulvarcancerversion pages 1-2, ha2024imaginginvulval pages 1-2, meng2024overallsurvivalassociated pages 1-2, iacobone2023tipsandtricks pages 2-4, nazeran2019bartholinglandcarcinoma pages 1-2, morais2022diagnosisandmanagement pages 1-2, lim2024wholegenomesequencing pages 1-2)

2. Etiology

2.1 Disease causal factors (current understanding)

Because “vulvar adenocarcinoma” is a category spanning multiple entities, etiology is subtype-dependent: - Bartholin gland primaries: etiologic inference is limited by rarity; HPV appears important for Bartholin SCC but not clearly established for adenocarcinoma. In a 13-case series, all Bartholin SCC showed diffuse p16, while the single adenocarcinoma showed patchy p16 staining. (nazeran2019bartholinglandcarcinoma pages 1-2) - Intestinal-type vulvar adenocarcinoma: proposed embryologic origins include cloacal remnants and other metaplasia hypotheses; inflammation and genetic changes are discussed. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 1-2, dellino2022“intestinaltype”vulvaradenocarcinoma pages 5-6) - EMPD: described as a rare neoplasm arising in apocrine-rich skin regions including vulva; molecular mechanisms include HER2 biology and alternative pathway activation (e.g., FGFR1/TGFβ enrichment in one WGS case). (lim2024wholegenomesequencing pages 1-2)

2.2 Risk factors

From NCCN Vulvar Cancer v3.2024 (applies to vulvar cancer overall; includes rare histologies): - Increasing age - HPV infection - Cigarette smoking - Inflammatory vulvar conditions - Immunodeficiency (aburustum2024vulvarcancerversion pages 1-2)

Intestinal-type VAIt review additionally lists exposures/conditions relevant to vulvar carcinogenesis broadly (lichen sclerosus/vulvar dystrophies, smoking, HPV infection) and environmental insults (infections, UV, physical damage), but without quantitative risk estimates for VAIt specifically. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 5-6)

For vulvar SCC pathogenesis context (important for mixed histology differential and prevention frameworks): HPV DNA is reported in ~40% of invasive vulvar cancers in one modern review, with HPV-associated tumors tending to occur in younger women and having better outcomes; HPV-independent tumors are associated with chronic dermatoses such as lichen sclerosus. (ayalapeacock2025advancesinvulvar pages 1-3)

2.3 Protective factors

No protective genetic or environmental factors specific to vulvar adenocarcinoma subtypes were identified in retrieved sources.

2.4 Gene–environment interactions

No explicit gene–environment interaction evidence specific to vulvar adenocarcinoma was identified in retrieved sources.

3. Phenotypes

3.1 Core clinical phenotypes (subtype-aware)

A. Vulvar EMPD (clinical phenotype and QoL impact) - Typical appearance: “erythematous, scaly or eczematous plaque on the vulva and perineum with occasional erosions or ulcerations, hypopigmentation and nodules” and symptoms: “Itching and burning pain”. (iacobone2023tipsandtricks pages 1-2) - High relapse burden: persistence/recurrence is common (86% in one cohort), often requiring repeated procedures. (iacobone2023tipsandtricks pages 2-4) - Cervico-vaginal spread can be clinically silent: “None reported vaginal bleeding or other suspicious symptoms” and detection was frequently via abnormal glandular cytology. (iacobone2023tipsandtricks pages 1-2)

Suggested HPO terms (examples): - Vulvar pruritus (HP:0031297; if unavailable, use “Pruritus” HP:0000989) - Burning pain (Pain; HP:0012531) - Erythematous skin lesion (HP:0025548) - Eczematous dermatitis (HP:0000964) - Vulvar mass (HP:0030417; if unavailable, “Mass” HP:0100242)

B. Bartholin-region carcinoma (including adenocarcinoma subtype) - Presents as a mass in the Bartholin region; diagnostic delay is common due to misclassification as cyst/abscess, motivating biopsy in women ≥40–45 with persistent/recurrent solid lesions. (kostov2025bartholinglandcarcinoma pages 20-21)

Suggested HPO terms: - Vulvar mass (HP:0030417), Vulvar pain (HP:0031242), Ulceration (HP:0001053)

C. Intestinal-type vulvar adenocarcinoma (VAIt) - Often presents as a solitary lesion in labia/perineal/posterior vulvar structures and may mimic benign lesions. (colalillo2025intestinaltypeadenocarcinomais pages 11-13, dellino2022“intestinaltype”vulvaradenocarcinoma pages 1-2)

3.2 Natural history and progression

• EMPD: persistent/relapsing course; cervico-vaginal involvement cumulative incidence increased over time (2.5% at 5 years, 6.5% at 10 years, 14.0% at 15 years). (iacobone2023tipsandtricks pages 1-2)
• FIGO staging and invasion: FIGO 2021 stage IA includes tumors ≤2 cm with stromal invasion ≤1 mm; stage IB includes >2 cm or invasion >1 mm. (ha2024imaginginvulval pages 1-2, ha2024imaginginvulval media 862afa93)

3.3 Quality of life impact

Direct QoL instruments specific to vulvar adenocarcinoma were not retrieved; however, EMPD symptom burden (itching/burning) and high recurrence requiring repeated interventions plausibly affects QoL and sexual function. (iacobone2023tipsandtricks pages 2-4, iacobone2023tipsandtricks pages 1-2)

4. Genetic/Molecular Information

4.1 Causal genes

No germline causal genes specific to “vulvar adenocarcinoma” as a disease category were identified in retrieved sources.

4.2 Somatic alterations, biomarkers, and IHC patterns (subtype-level)

A. Vulvar EMPD / Paget-associated vulvar adenocarcinoma - HER2 biology is clinically important. In a WGS case report and literature synthesis, HER2 overexpression in EMPD series was reported as 15–65%, with ERBB2 amplification 13–43%; in the case, >90% tumor cells stained HER2+ with ≥40% showing 3+ intensity. (lim2024wholegenomesequencing pages 2-4) - WGS found copy number gains on chromosomes 7 and 8 (n=81 genes, 92.6% on chr8) and pathway enrichment for TGFβ and FGFR1 signaling; notably “ERBB2 gene did not exhibit high copy number gain… although 90% of tumor cells stained HER2-positive”, suggesting overexpression without strong ERBB2 CN gain in that case. (lim2024wholegenomesequencing pages 1-2)

Mechanistic interpretation (expert analysis): These findings support a model where HER2 protein overexpression can occur via mechanisms beyond high-level ERBB2 amplification (e.g., regulatory/structural alterations), and where parallel signaling (FGFR1/TGFβ) may modulate response/resistance to HER2-directed therapy. (lim2024wholegenomesequencing pages 1-2)

B. Mammary-like / mammary gland type adenocarcinoma (AMGT) of the vulva - IHC profile can resemble breast carcinoma: strong ER positivity (reported 90–100%), CK7/CAM5.2/GATA3 positivity; typically negative for PR, GCDFP-15, SOX10, p63, CK20. HER2 may be equivocal (2+) with FISH negative in a case. (morais2022diagnosisandmanagement pages 1-2) - Key diagnostic principle is exclusion of a breast primary by clinical and imaging workup. (morais2022diagnosisandmanagement pages 1-2)

C. Intestinal-type vulvar adenocarcinoma (VAIt) - Characteristic “intestinal” IHC phenotype: frequent CK20 and CDX2 positivity, often CEA positive, variable CK7 and p16; requires exclusion of metastatic colorectal primary. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 1-2, colalillo2025intestinaltypeadenocarcinomais pages 11-13)

D. Bartholin gland carcinoma (with adenocarcinoma subtype) - In a 13-case cohort (1984–2017), Bartholin SCC showed diffuse p16; the single adenocarcinoma showed patchy p16 staining. (nazeran2019bartholinglandcarcinoma pages 1-2) - Reporting standards emphasize diagnosing primary Bartholin gland origin by anatomic region involvement, compatible histology, no other primary identified, and preferably adjacent normal Bartholin gland tissue. (faruqi2018standardsanddatasets pages 12-16)

4.3 Epigenetics / chromosomal abnormalities

Not specifically identified for vulvar adenocarcinoma subtypes in retrieved evidence.

4.4 Suggested pathway and ontology terms

Pathways (GO biological process suggestions): - ERBB2 signaling pathway / receptor tyrosine kinase signaling (GO:0007169; broad) - PI3K-AKT signaling (useful for HER2/PTEN context; supported indirectly via trastuzumab resistance mechanisms and HER2 pathway emphasis) (lim2024wholegenomesequencing pages 1-2) - TGFβ receptor signaling pathway (GO:0007179) (lim2024wholegenomesequencing pages 1-2) - FGFR signaling pathway (GO:0008543) (lim2024wholegenomesequencing pages 1-2)

Cell types (Cell Ontology suggestions): - Keratinocyte / epithelial cell (CL:0000312; generic epithelium) - Glandular epithelial cell / secretory epithelial cell (useful for adenocarcinoma and apocrine-associated EMPD) (lim2024wholegenomesequencing pages 1-2)

5. Environmental Information

• Lifestyle/environmental factors (vulvar cancer overall): smoking is a risk factor per NCCN 2024. (aburustum2024vulvarcancerversion pages 1-2)
• Inflammatory vulvar conditions: risk factor per NCCN; HPV-independent pathway often linked to chronic dermatoses (e.g., lichen sclerosus) in SCC literature, relevant for differential diagnosis and prevention frameworks. (aburustum2024vulvarcancerversion pages 1-2, ayalapeacock2025advancesinvulvar pages 1-3)
• Infectious agents: HPV infection is a recognized risk factor for vulvar cancer; HPV’s role in VAIt is described as ambiguous in older systematic review, and Bartholin SCC appears HPV-associated by p16. (aburustum2024vulvarcancerversion pages 1-2, nazeran2019bartholinglandcarcinoma pages 1-2, dellino2022“intestinaltype”vulvaradenocarcinoma pages 9-10)

6. Mechanism / Pathophysiology

6.1 Subtype-specific causal chains (high-level)

A. EMPD / Paget-associated adenocarcinoma 1) Transformation of apocrine-rich cutaneous epithelium into Paget cells within epidermis.
2) Potential progression to stromal invasion and/or association with an underlying adenocarcinoma (Wilkinson/Brown Type 1b/1c).
3) Molecular drivers may include HER2 overexpression; alternative signaling (FGFR1/TGFβ) may contribute to aggressive/metastatic behavior and treatment response/resistance. (iacobone2023tipsandtricks pages 2-4, lim2024wholegenomesequencing pages 1-2)

B. Intestinal-type vulvar adenocarcinoma 1) Proposed embryologic substrate (persistent cloacal remnants or metaplastic intestinal epithelium).
2) Development of colorectal-like glandular neoplasm with intestinal differentiation.
3) Clinical manifestation as vulvar/perineal lesion; important downstream step is ruling out metastatic colorectal carcinoma. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 1-2, dellino2022“intestinaltype”vulvaradenocarcinoma pages 5-6)

C. Mammary-like gland adenocarcinoma 1) Malignant transformation of mammary-like vulvar glands.
2) Breast-carcinoma-like morphology and ER-driven biology.
3) Clinical implication: requires exclusion of metastatic breast primary and may suggest endocrine-therapy relevance (inferred from ER positivity; treatment decisions are individualized). (morais2022diagnosisandmanagement pages 1-2)

7. Anatomical Structures Affected

7.1 Organ/tissue level (UBERON suggestions)

• Vulva (UBERON:0000997)
• Labia majora/minora (UBERON terms)
• Bartholin gland (greater vestibular gland) (UBERON term; implicated in Bartholin primaries) (nazeran2019bartholinglandcarcinoma pages 1-2)
• Perineum / anogenital region (relevant for EMPD distribution) (lim2024wholegenomesequencing pages 1-2)
• Cervix and vagina (for cervico-vaginal involvement in EMPD) (iacobone2023tipsandtricks pages 1-2)

7.2 Subcellular

Not specifically addressed in retrieved evidence.

8. Temporal Development

• Typical onset: vulvar cancers are more common with increasing age; EMPD typical age 60–80 years; EMPD cohort mean 63.3 years. (aburustum2024vulvarcancerversion pages 1-2, lim2024wholegenomesequencing pages 1-2, iacobone2023tipsandtricks pages 2-4)
• Course: EMPD is often chronic/relapsing (local recurrence after excision reported up to 73% in literature; cohort persistence/recurrence 86%). (iacobone2023tipsandtricks pages 1-2, iacobone2023tipsandtricks pages 2-4)
• Late events: cervico-vaginal involvement may occur very late (example: 251 months after initial vulvar EMPD). (iacobone2023tipsandtricks pages 6-9)

9. Inheritance and Population

9.1 Epidemiology

• Global burden (vulvar cancer overall): ~47,000 cases in 2022 reported in a 2024 imaging review. (ha2024imaginginvulval pages 1-2)
• US annual diagnoses (vulvar cancer overall): NCCN cites ~6,470 annually. (aburustum2024vulvarcancerversion pages 1-2)
• EMPD incidence: 0.1–2.4 per million per year; ~20% present with distant metastatic disease. (lim2024wholegenomesequencing pages 1-2)

9.2 Sex ratio

• Vulvar cancers occur in individuals with vulvar anatomy; EMPD also occurs in male genital region (case report). (lim2024wholegenomesequencing pages 1-2)

9.3 Genetics/inheritance

No Mendelian inheritance pattern is established for vulvar adenocarcinoma in retrieved evidence.

10. Diagnostics

10.1 Clinical and pathology diagnosis

• Biopsy is required for definitive diagnosis of vulvar lesions; vulvoscopy helps identify optimal biopsy sites. (corte2024currentpreoperativemanagement pages 1-2, kesic2022earlydiagnosticsof pages 1-2)

EMPD cervico-vaginal extension diagnostic pathway (referral center practice): - “All cases except one were firstly detected by abnormal glandular cytology.” (iacobone2023tipsandtricks pages 1-2) - Abnormal cytology prompted colposcopy and cervical/vaginal biopsies; HPV testing negative in CV EMPD cases; HER2 immunocytochemistry used on cell blocks in some cases. (iacobone2023tipsandtricks pages 6-9)

Differential diagnosis (key points): - Mammary-like vulvar adenocarcinoma requires exclusion of breast primary (mammography/US/PET used in reported cases). (morais2022diagnosisandmanagement pages 1-2) - Intestinal-type vulvar adenocarcinoma requires exclusion of metastatic colorectal carcinoma; CDX2/CK20/CK7 patterns aid. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 1-2) - EMPD secondary disease exclusion can use CDX-2 and uroplakin-III (and other panels) to rule out colorectal/urothelial origins. (iacobone2023tipsandtricks pages 9-10)

10.2 Imaging and staging

FIGO 2021 staging table (visual evidence): see Table 1 image (ha2024imaginginvulval media 862afa93).

Imaging recommendations by stage (guideline-synthesis): - No routine imaging for clinically FIGO stage IA. (ha2024imaginginvulval pages 2-4) - Pelvic MRI for local staging in tumors with invasion >1 mm, larger size (e.g., >4 cm), or suspected extension to urethra/vagina/anus. (ha2024imaginginvulval pages 2-4) - For advanced or metastatic disease: CT chest/abdomen/pelvis or FDG-PET/CT. (ha2024imaginginvulval pages 2-4)

Imaging performance statistics (vulvar cancer literature; mostly SCC but used clinically across histologies): - MRI nodal sensitivity highly variable (≈40–52% up to 86–89%), specificity generally high (≈82–100%). CT sensitivity low (≈43–58%). (ha2024imaginginvulval pages 4-5) - Meta-analysis referenced in imaging review: PET/CT per-patient sensitivity 70%, specificity 90%. (ha2024imaginginvulval pages 5-7) - Vulvoscopy diagnostic metrics in a 2024 overview: sensitivity 98%, specificity 40%, NPV 98% for malignant lesions. (corte2024currentpreoperativemanagement pages 1-2)

11. Outcome/Prognosis

11.1 EMPD outcomes

• In a 94-woman vulvar EMPD cohort: 5-year OS 90.5% (95% CI 81.8–95.1%), persistence/recurrence 86%, median 2 surgeries (0–11). (iacobone2023tipsandtricks pages 2-4)

11.2 Nodal status prognostic impact (vulvar cancer overall)

• 2-year disease-free survival reported as 88% (node-negative) vs 60% / 43% / 29% for 1 / 2 / >2 positive nodes, respectively. (ha2024imaginginvulval pages 1-2)

11.3 Bartholin gland carcinoma outcomes

• In a 13-case cohort: 9 (75%) disease-free at mean follow-up 53.7 months; 3 recurrences; 2 disease-specific deaths among those with recurrence, including the adenocarcinoma case. (nazeran2019bartholinglandcarcinoma pages 1-2)

11.4 Metastatic vulvar cancer (SEER)

• Chemoradiotherapy associated with improved OS vs radiotherapy alone in propensity-matched cohort (HR 0.7367, 95% CI 0.5906–0.9190; P=0.0049). (meng2024overallsurvivalassociated pages 1-2)

12. Treatment

12.1 Guideline-based management framework (vulvar cancer overall; rare histologies acknowledged)

NCCN v3.2024 provides stage-based management for vulvar cancer and explicitly includes rare histologies such as extramammary Paget’s disease and Bartholin gland adenocarcinoma in its scope of “rarer histologies”. (aburustum2024vulvarcancerversion pages 1-2)

12.2 Subtype-oriented treatments and real-world implementations

A. EMPD (including noninvasive disease) — local and topical treatments - In practice, surgery is common (92/94 in one cohort), and relapse management includes topical imiquimod (63%), photodynamic therapy (5%), and radiotherapy (12%). (iacobone2023tipsandtricks pages 2-4, iacobone2023tipsandtricks pages 4-6)

B. HER2-directed systemic therapy for metastatic EMPD - A WGS case report described rapid response to paclitaxel plus trastuzumab in HER2+ de novo metastatic EMPD. (lim2024wholegenomesequencing pages 2-4)

C. Bartholin gland carcinoma/adenocarcinoma - Management is often extrapolated from vulvar cancer; experts emphasize molecular profiling (DNA panels with CNV, RNA fusions, MSI/TMB/PD-L1) to reduce misclassification and enable targeted/immunotherapy in advanced disease. (kostov2025bartholinglandcarcinoma pages 20-21)

12.3 Clinical trials (selected; real-world implementability)

Topical imiquimod trials (noninvasive vulvar Paget/EMPD): - NCT02385188 (Phase 3; completed; n=25): topical 5% imiquimod 3×/week for 16 weeks; primary endpoint clinical response 12 weeks after end of treatment; includes QoL instruments (EQ-5D, DLQI, FSDS). (NCT02385188 chunk 1) - NCT00504023 (pilot; completed; n=8): imiquimod 3×/week up to 12 weeks; biopsies at baseline and 12 weeks; follow-up every 3 months for ≥2 years. (NCT00504023 chunk 1)

Photodynamic therapy device trial: - NCT03713203 (Phase II; recruiting; n=24): PAGETEX® device with Metvixia; 2–4 PDT sessions; primary endpoint disease control rate at 3 months; excludes invasive disease/underlying adenocarcinoma. (NCT03713203 chunk 1)

Systemic/advanced vulvar cancer trial example: - NCT03452332 (Phase 1; completed): SBRT + tremelimumab + durvalumab in recurrent/metastatic cervical/vaginal/vulvar cancers. (trial record retrieved but not evidence-extracted in provided snippets; use cautiously)

12.4 MAXO term suggestions (examples)

• Surgical excision/vulvectomy: MAXO: surgical excision (generic)
• Radiotherapy: MAXO: radiotherapy
• Chemotherapy (platinum/taxane): MAXO: chemotherapy
• HER2-directed therapy (trastuzumab): MAXO: targeted therapy / monoclonal antibody therapy
• Topical imiquimod: MAXO: topical immunotherapy
• Photodynamic therapy: MAXO: photodynamic therapy

13. Prevention

• Risk factor modification (general vulvar cancer): NCCN identifies smoking, HPV, inflammatory vulvar conditions, and immunodeficiency as risk factors; these support prevention via smoking cessation, HPV prevention/control, and treatment of chronic vulvar inflammatory disease, although explicit preventive recommendations were not present in the retrieved NCCN excerpt. (aburustum2024vulvarcancerversion pages 1-2)
• Secondary prevention: early biopsy of suspicious vulvar lesions and careful evaluation of VIN/lichen sclerosus are emphasized in diagnostic reviews; brush cytology is investigated as triage for VIN but biopsy remains gold standard. (kesic2022earlydiagnosticsof pages 1-2)

Evidence gap: explicit HPV vaccination impact on vulvar adenocarcinoma or adenocarcinoma-specific prevention strategies were not retrieved.

14. Other Species / Natural Disease

No evidence identified in retrieved sources.

15. Model Organisms

A trastuzumab-resistant EMPD model is reported with PTEN loss as a potential resistance mechanism (supporting mechanistic research and therapy optimization), but detailed model description was not extracted in current evidence snippets. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 1-2, lim2024wholegenomesequencing pages 1-2)

Key Recent Developments (prioritizing 2023–2024)

1. NCCN Vulvar Cancer v3.2024 explicitly contextualizes rarer histologies including Bartholin gland adenocarcinoma and EMPD within a unified management framework and lists key risk factors. Publication: Mar 2024; URL: https://doi.org/10.6004/jnccn.2024.0013 (aburustum2024vulvarcancerversion pages 1-2)
2. Imaging and FIGO 2021 staging implementation (2024): staging applicability to non-melanoma vulvar cancers and imaging recommendations by stage; provides pooled PET/CT performance and highlights limitations. Publication: Jun 2024; URL: https://doi.org/10.3390/cancers16122269 (ha2024imaginginvulval pages 1-2, ha2024imaginginvulval pages 2-4, ha2024imaginginvulval pages 5-7, ha2024imaginginvulval media 862afa93)
3. Genomics-enabled precision approaches in EMPD (2024): WGS of HER2+ metastatic EMPD documents CNV landscape, pathway enrichment (FGFR1/TGFβ), and clinical response to HER2-directed therapy combined with chemotherapy. Publication: Jun 2024; URL: https://doi.org/10.1186/s13023-024-03169-y (lim2024wholegenomesequencing pages 2-4, lim2024wholegenomesequencing pages 1-2)
4. Refined long-term surveillance concept for vulvar EMPD (2023): referral-center data quantify recurrence and late cervico-vaginal involvement; supports lifelong follow-up and cytology/biopsy-based detection. Publication: Jan 2023; URL: https://doi.org/10.3390/diagnostics13030464 (iacobone2023tipsandtricks pages 2-4, iacobone2023tipsandtricks pages 1-2)

Summary Table (Subtype comparison)

Table: This table compares the main vulvar adenocarcinoma-related entities identified in the gathered evidence, emphasizing diagnostic markers, management patterns, and quantitative outcomes. It is useful for quickly distinguishing subtype-specific features while keeping evidence provenance explicit through context-ID citations.

Visual Evidence: FIGO 2021 staging

The FIGO 2021 staging table for vulvar carcinoma (applies to all morphologic types except melanoma) is shown in the extracted Table 1 image. (ha2024imaginginvulval media 862afa93)

Limitations and Data Gaps

• Ontology IDs (MONDO/MeSH/Orphanet/OMIM): Not retrievable from current tool outputs for “vulvar adenocarcinoma” and will need direct ontology database lookup outside this toolchain.
• Adenocarcinoma-specific population incidence/survival: Most quantitative epidemiology is for vulvar cancer overall or for specific rare entities (EMPD, Bartholin cohorts, VAIt systematic reviews). Large 2023–2024 population studies stratified by vulvar adenocarcinoma subtypes were not available in retrieved evidence.
• Genetic predisposition and protective factors: Not identified in retrieved sources.

References

1. (aburustum2024vulvarcancerversion pages 1-2): Nadeem R. Abu-Rustum, Catheryn M. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susana M. Campos, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli, Scott Glaser, Jordan Holmes, Brooke E. Howitt, Kari Kendra, Jayanthi Lea, Nita Lee, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole McMillian, and Sara Espinosa. Vulvar cancer, version 3.2024, nccn clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 22 2:117-135, Mar 2024. URL: https://doi.org/10.6004/jnccn.2024.0013, doi:10.6004/jnccn.2024.0013. This article has 88 citations.

2. (ha2024imaginginvulval pages 1-2): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.

3. (muigai2018potentialdelayin pages 1-2): Jennifer Muigai, Louis Jacob, Konstantinos Dinas, Karel Kostev, and Matthias Kalder. Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in german gynecological practices. Oncotarget, 9:8725-8730, Jan 2018. URL: https://doi.org/10.18632/oncotarget.23848, doi:10.18632/oncotarget.23848. This article has 45 citations.

4. (ha2024imaginginvulval media 862afa93): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.

5. (faruqi2018standardsanddatasets pages 12-16): A Faruqi and B Rous. Standards and datasets for reporting cancers. Unknown journal, 2018.

6. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 1-2): Miriam Dellino, Stefania Cicogna, Francesca Falcone, Marco Mitidieri, Roberta Mazzeo, Sandro Pignata, Giorgia Mangili, and Gennaro Cormio. “intestinal-type” vulvar adenocarcinoma: a review of the mito rare tumors group. Cancers, 14:5171, Oct 2022. URL: https://doi.org/10.3390/cancers14205171, doi:10.3390/cancers14205171. This article has 9 citations.

7. (morais2022diagnosisandmanagement pages 1-2): Mariana Morais, Joao Vaz Silva, and Mariana Vide Tavares. Diagnosis and management of primary vulvar adenocarcinoma of mammary gland type: report of two distinct cases. BMJ Case Reports, 15:e245580, Jun 2022. URL: https://doi.org/10.1136/bcr-2021-245580, doi:10.1136/bcr-2021-245580. This article has 15 citations and is from a peer-reviewed journal.

8. (iacobone2023tipsandtricks pages 2-4): Anna Daniela Iacobone, Maria Elena Guerrieri, Eleonora Petra Preti, Noemi Spolti, Gianluigi Radici, Giulia Peveri, Vincenzo Bagnardi, Giulio Tosti, Angelo Maggioni, Fabio Bottari, Chiara Scacchi, and Mariacristina Ghioni. Tips and tricks for early diagnosis of cervico-vaginal involvement from extramammary paget’s disease of the vulva: a referral center experience. Diagnostics, 13:464, Jan 2023. URL: https://doi.org/10.3390/diagnostics13030464, doi:10.3390/diagnostics13030464. This article has 3 citations.

9. (meng2024overallsurvivalassociated pages 1-2): Xiaolin Meng, Shuaiqingying Guo, Xue Feng, Jihui Ai, and Jie Yang. Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: a retrospective cohort study based on the seer database. Cancer Pathogenesis and Therapy, 2:195-204, Jul 2024. URL: https://doi.org/10.1016/j.cpt.2023.08.003, doi:10.1016/j.cpt.2023.08.003. This article has 6 citations.

10. (nazeran2019bartholinglandcarcinoma pages 1-2): Tayyebeh Nazeran, Angela S. Cheng, Anthony N. Karnezis, Anna V. Tinker, and C. Blake Gilks. Bartholin gland carcinoma: clinicopathologic features, including p16 expression and clinical outcome. International Journal of Gynecological Pathology, 38:189-195, Mar 2019. URL: https://doi.org/10.1097/pgp.0000000000000489, doi:10.1097/pgp.0000000000000489. This article has 40 citations and is from a peer-reviewed journal.

11. (lim2024wholegenomesequencing pages 1-2): Boon Yee Lim, Zexi Guo, Jing Quan Lim, Tun Kiat Ko, Elizabeth Chun Yong Lee, Bavani Kannan, Jing Yi Lee, Abner Herbert Lim, Zhimei Li, Cedric Chuan-Young Ng, Inny Busmanis, and Jason Yongsheng Chan. Whole genome sequencing of her2-positive metastatic extramammary paget’s disease: a case report. Orphanet Journal of Rare Diseases, Jun 2024. URL: https://doi.org/10.1186/s13023-024-03169-y, doi:10.1186/s13023-024-03169-y. This article has 1 citations and is from a peer-reviewed journal.

12. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 5-6): Miriam Dellino, Stefania Cicogna, Francesca Falcone, Marco Mitidieri, Roberta Mazzeo, Sandro Pignata, Giorgia Mangili, and Gennaro Cormio. “intestinal-type” vulvar adenocarcinoma: a review of the mito rare tumors group. Cancers, 14:5171, Oct 2022. URL: https://doi.org/10.3390/cancers14205171, doi:10.3390/cancers14205171. This article has 9 citations.

13. (ayalapeacock2025advancesinvulvar pages 1-3): Diandra N. Ayala-Peacock and Manjeet Chadha. Advances in vulvar cancer: a radiation oncology perspective. Cancers, 17:2415, Jul 2025. URL: https://doi.org/10.3390/cancers17152415, doi:10.3390/cancers17152415. This article has 1 citations.

14. (iacobone2023tipsandtricks pages 1-2): Anna Daniela Iacobone, Maria Elena Guerrieri, Eleonora Petra Preti, Noemi Spolti, Gianluigi Radici, Giulia Peveri, Vincenzo Bagnardi, Giulio Tosti, Angelo Maggioni, Fabio Bottari, Chiara Scacchi, and Mariacristina Ghioni. Tips and tricks for early diagnosis of cervico-vaginal involvement from extramammary paget’s disease of the vulva: a referral center experience. Diagnostics, 13:464, Jan 2023. URL: https://doi.org/10.3390/diagnostics13030464, doi:10.3390/diagnostics13030464. This article has 3 citations.

15. (kostov2025bartholinglandcarcinoma pages 20-21): Stoyan Kostov, Yavor Kornovski, Vesela Ivanova, Dimitar Metodiev, Angel Yordanov, Stanislav Slavchev, Yonka Ivanova, Anke Seidel, Ingolf Juhasz-Böss, Ihsan Hasan, Ibrahim Alkatout, and Rafał Watrowski. Bartholin gland carcinoma: a state-of-the-art review of epidemiology, histopathology, molecular testing, and clinical management. Cancers, 17:3819, Nov 2025. URL: https://doi.org/10.3390/cancers17233819, doi:10.3390/cancers17233819. This article has 2 citations.

16. (colalillo2025intestinaltypeadenocarcinomais pages 11-13): Alessio Colalillo, Dominga Boccia, Luigi Della Corte, Daniele Neola, Federica Rosato, Silvia D’Ippolito, Maria De Ninno, Damiano Arciuolo, Maurizio Guida, Giuseppe Bifulco, and Francesco Cosentino. Intestinal-type adenocarcinoma is a rare histotype of vulvar neoplasm: systematic review of the literature. Cancers, 17:3989, Dec 2025. URL: https://doi.org/10.3390/cancers17243989, doi:10.3390/cancers17243989. This article has 0 citations.

17. (lim2024wholegenomesequencing pages 2-4): Boon Yee Lim, Zexi Guo, Jing Quan Lim, Tun Kiat Ko, Elizabeth Chun Yong Lee, Bavani Kannan, Jing Yi Lee, Abner Herbert Lim, Zhimei Li, Cedric Chuan-Young Ng, Inny Busmanis, and Jason Yongsheng Chan. Whole genome sequencing of her2-positive metastatic extramammary paget’s disease: a case report. Orphanet Journal of Rare Diseases, Jun 2024. URL: https://doi.org/10.1186/s13023-024-03169-y, doi:10.1186/s13023-024-03169-y. This article has 1 citations and is from a peer-reviewed journal.

18. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 9-10): Miriam Dellino, Stefania Cicogna, Francesca Falcone, Marco Mitidieri, Roberta Mazzeo, Sandro Pignata, Giorgia Mangili, and Gennaro Cormio. “intestinal-type” vulvar adenocarcinoma: a review of the mito rare tumors group. Cancers, 14:5171, Oct 2022. URL: https://doi.org/10.3390/cancers14205171, doi:10.3390/cancers14205171. This article has 9 citations.

19. (iacobone2023tipsandtricks pages 6-9): Anna Daniela Iacobone, Maria Elena Guerrieri, Eleonora Petra Preti, Noemi Spolti, Gianluigi Radici, Giulia Peveri, Vincenzo Bagnardi, Giulio Tosti, Angelo Maggioni, Fabio Bottari, Chiara Scacchi, and Mariacristina Ghioni. Tips and tricks for early diagnosis of cervico-vaginal involvement from extramammary paget’s disease of the vulva: a referral center experience. Diagnostics, 13:464, Jan 2023. URL: https://doi.org/10.3390/diagnostics13030464, doi:10.3390/diagnostics13030464. This article has 3 citations.

20. (corte2024currentpreoperativemanagement pages 1-2): Luigi Della Corte, Valeria Cafasso, Maria Chiara Guarino, Giuseppe Gullo, Gaspare Cucinella, Alessandra Lopez, Simona Zaami, Gaetano Riemma, Pierluigi Giampaolino, and Giuseppe Bifulco. Current preoperative management of vulvar squamous cell carcinoma: an overview. Cancers, 16:1846, May 2024. URL: https://doi.org/10.3390/cancers16101846, doi:10.3390/cancers16101846. This article has 12 citations.

21. (kesic2022earlydiagnosticsof pages 1-2): Vesna Kesić, Pedro Vieira-Baptista, and Colleen K. Stockdale. Early diagnostics of vulvar intraepithelial neoplasia. Cancers, 14:1822, Apr 2022. URL: https://doi.org/10.3390/cancers14071822, doi:10.3390/cancers14071822. This article has 38 citations.

22. (iacobone2023tipsandtricks pages 9-10): Anna Daniela Iacobone, Maria Elena Guerrieri, Eleonora Petra Preti, Noemi Spolti, Gianluigi Radici, Giulia Peveri, Vincenzo Bagnardi, Giulio Tosti, Angelo Maggioni, Fabio Bottari, Chiara Scacchi, and Mariacristina Ghioni. Tips and tricks for early diagnosis of cervico-vaginal involvement from extramammary paget’s disease of the vulva: a referral center experience. Diagnostics, 13:464, Jan 2023. URL: https://doi.org/10.3390/diagnostics13030464, doi:10.3390/diagnostics13030464. This article has 3 citations.

23. (ha2024imaginginvulval pages 2-4): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.

24. (ha2024imaginginvulval pages 4-5): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.

25. (ha2024imaginginvulval pages 5-7): Minah Ha and Lois Eva. Imaging in vulval cancer. Cancers, 16:2269, Jun 2024. URL: https://doi.org/10.3390/cancers16122269, doi:10.3390/cancers16122269. This article has 5 citations.

26. (iacobone2023tipsandtricks pages 4-6): Anna Daniela Iacobone, Maria Elena Guerrieri, Eleonora Petra Preti, Noemi Spolti, Gianluigi Radici, Giulia Peveri, Vincenzo Bagnardi, Giulio Tosti, Angelo Maggioni, Fabio Bottari, Chiara Scacchi, and Mariacristina Ghioni. Tips and tricks for early diagnosis of cervico-vaginal involvement from extramammary paget’s disease of the vulva: a referral center experience. Diagnostics, 13:464, Jan 2023. URL: https://doi.org/10.3390/diagnostics13030464, doi:10.3390/diagnostics13030464. This article has 3 citations.

27. (NCT02385188 chunk 1): Joanne A. de Hullu, MD, PhD. Topical 5% Imiquimod Cream for Vulvar Paget's Disease. University Medical Center Nijmegen. 2015. ClinicalTrials.gov Identifier: NCT02385188

28. (NCT00504023 chunk 1): Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva. Memorial Sloan Kettering Cancer Center. 2007. ClinicalTrials.gov Identifier: NCT00504023

29. (NCT03713203 chunk 1): PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).. University Hospital, Lille. 2019. ClinicalTrials.gov Identifier: NCT03713203

30. (dellino2022“intestinaltype”vulvaradenocarcinoma pages 2-5): Miriam Dellino, Stefania Cicogna, Francesca Falcone, Marco Mitidieri, Roberta Mazzeo, Sandro Pignata, Giorgia Mangili, and Gennaro Cormio. “intestinal-type” vulvar adenocarcinoma: a review of the mito rare tumors group. Cancers, 14:5171, Oct 2022. URL: https://doi.org/10.3390/cancers14205171, doi:10.3390/cancers14205171. This article has 9 citations.

31. (colalillo2025intestinaltypeadenocarcinomais pages 1-2): Alessio Colalillo, Dominga Boccia, Luigi Della Corte, Daniele Neola, Federica Rosato, Silvia D’Ippolito, Maria De Ninno, Damiano Arciuolo, Maurizio Guida, Giuseppe Bifulco, and Francesco Cosentino. Intestinal-type adenocarcinoma is a rare histotype of vulvar neoplasm: systematic review of the literature. Cancers, 17:3989, Dec 2025. URL: https://doi.org/10.3390/cancers17243989, doi:10.3390/cancers17243989. This article has 0 citations.

32. (colalillo2025intestinaltypeadenocarcinomais pages 10-11): Alessio Colalillo, Dominga Boccia, Luigi Della Corte, Daniele Neola, Federica Rosato, Silvia D’Ippolito, Maria De Ninno, Damiano Arciuolo, Maurizio Guida, Giuseppe Bifulco, and Francesco Cosentino. Intestinal-type adenocarcinoma is a rare histotype of vulvar neoplasm: systematic review of the literature. Cancers, 17:3989, Dec 2025. URL: https://doi.org/10.3390/cancers17243989, doi:10.3390/cancers17243989. This article has 0 citations.

33. (kostov2025bartholinglandcarcinoma pages 24-25): Stoyan Kostov, Yavor Kornovski, Vesela Ivanova, Dimitar Metodiev, Angel Yordanov, Stanislav Slavchev, Yonka Ivanova, Anke Seidel, Ingolf Juhasz-Böss, Ihsan Hasan, Ibrahim Alkatout, and Rafał Watrowski. Bartholin gland carcinoma: a state-of-the-art review of epidemiology, histopathology, molecular testing, and clinical management. Cancers, 17:3819, Nov 2025. URL: https://doi.org/10.3390/cancers17233819, doi:10.3390/cancers17233819. This article has 2 citations.